Our goal is to be flexible, responsive, and honest within a partnership of equals designed to deliver value for both parties. When a potential partner has submitted a proposal, we are committed to giving a prompt, tailored response within two weeks. For consistency, AstraZeneca follows a carefully defined partnering process involving four sequential gateways (or “Gates”) from evaluation through to contract signature. We are open and transparent throughout the partnering process, sharing our scientific, regulatory and commercial insights and expertise at each stage. Even if our discussions do not proceed to the next gateway in the transaction process, we will strive to provide meaningful, honest and constructive feedback.
Our evaluation criteria
We assess all projects, whether internal or externally derived, against our "5 Rs" evaluation criteria: Right target, Right tissue/exposure, Right safety, Right patients, Right commercial that ensures we take forward the most attractive opportunities, regardless of source. These criteria also provide a framework for consistent and objective feedback to our partners, whether we decide to move forward with the opportunity or not.
- Strong link between target and disease
- Differentiating efficacy
- Available and predictive biomarkers
Right tissue / exposure
- Adequate bioavailability and tissue exposure
- Human Pharmacokinetics/ Pharmacodynamics (PD) prediction
- PD biomarkers
- Drug-drug interaction
- Clear assessment of safety risks
- Clear understanding of risk/benefit
- Availability of predictive biomarkers
- Scientific evidence in lead indication
- Risk/benefit stratification of patient population
- Personalised healthcare strategy including diagnostic / biomarkers
- Differentiated value proposition vs. future standard of care
- Priority geographies
- Market access/ payer/provider focus
- Personalised healthcare strategy including diagnostic/ biomarkers
At AstraZeneca we are committed to creating strong, long-term partnerships that will speed the delivery of innovative new medicines to the people that need them. Experience tells us that when partnerships aren’t actively managed, the potential value to both partners is jeopardised.
Our Alliance and Integration Management team is engaged throughout the deal process, starting as early as due diligence and contract negotiations. Gaining an early understanding of the strategic, operational and cultural fit between AstraZeneca and our partners enables us to structure the partnership governance and staff the
partnership to be most effective right from the start.
Whether engaging in early-stage research collaborations and academic alliances, co-development or co-promotion partnerships, or acquisitions or externalisation of innovative products, we believe that the most successful relationships are built on trust and transparency. We are committed to forging strong relationships with our partners at all levels of the enterprise.
Signing the deal is just the beginning
We assign a dedicated Alliance and Integration Management professional early in the evaluation stage who will remain your key contact throughout the collaboration.
Based on our extensive work in a wide range of complex business and scientific collaborations, we have developed industry leading processes and tools that ensure a smooth acquisition integration or a successful alliance execution.
We actively monitor and regularly assess the performance of our partnerships, embedding the learnings in new ventures.
Please get in contact with a member of our Alliance and Integration Management team if you would like to discuss any aspect of your partnering experience with us.
We genuinely welcome your feedback.